Plain-English translation of NCT05024929 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study is following patients with differentiated thyroid cancer that has spread to the lungs who are receiving targeted therapy — medications designed to attack specific genetic mutations in their cancer cells. Researchers want to understand how these targeted therapies work by taking imaging scans before and after about 4 weeks of treatment to see if the cancer becomes more sensitive to radioactive iodine, a powerful treatment option for thyroid cancer.
Some thyroid cancers stop responding to radioactive iodine over time, which limits treatment options for patients. This study is exploring whether targeted therapy can 'wake up' cancer cells and make them responsive to radioactive iodine again, potentially opening new treatment paths for patients with advanced thyroid cancer.
You likely qualify if…
You likely don't qualify if…
If you join this study, you would start your targeted therapy as planned with your doctor. About 4 weeks after starting the medication, you would come for a whole-body imaging scan (called a thyroid scan) to see how your cancer is responding — this is a standard test that takes a few hours and involves receiving a small amount of radioactive material by mouth. Your doctor will then continue your cancer treatment as they normally would, and the research team will use your scan results to understand whether the medication helped make your tumors more sensitive to radioactive iodine treatment.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States